clinical trial · NCT06925737
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 1,440
Prostate CancerProstatic NeoplasmsIfinatamab deruxtecanDocetaxelPrednisoneRescue Medication
brief summary
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
started
May 13, 2025
primary completion
Jun 26, 2028
completion
Jan 6, 2031
last updated
May 15, 2026
official title
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol